SCHEMBL21789039

SCHEMBL21789039

COC(=O)CN(Cc1cccs1)C(=O)[C@H](NC(=O)OC(C)(C)C)c1ccccc1OC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.44
POLB P06746 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
OGT O15294 1/20 0.42
CTSK P43235 2/20 0.41
CTSS P25774 1/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
CACNA1B Q00975 1/20 0.38
MEN1 O00255 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21788946 0.93 ALDH1A1 (0.45) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL21777358 0.93 MAPT (0.47) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL21777359 0.93 MAPT (0.47) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL21777440 0.91 PPARG (0.42) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL17407152 0.86 OGT (0.57) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL21777274 0.83 ALDH1A1 (0.41) MAPTALDH1A1POLBNPSR1OGT
SCHEMBL24002213 0.80 MAPT (0.50) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL29460074 0.80 ALDH1A1 (0.49) MAPTALDH1A1POLBNPSR1PKM
SCHEMBL15238520 0.75 CTSK (0.51) ALDH1A1POLBTSHRCTSKCTSS
SCHEMBL23357774 0.75 CTSK (0.46) MAPTALDH1A1POLBNPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582644-B2 O-GlcNAc transferase inhibitors and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2026-03-24 US disclosed
US-20210346367-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-11-11 US disclosed
WO-2020047251-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582644-B2 O-GlcNAc transferase inhibitors and uses thereof OGA, OGT, OSTC MAPT 62/4885ALDH1A1 1506/4885POLB 608/4885
US-20210346367-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF OGT, OGA, UGGT1 MAPT 34/4885ALDH1A1 1594/4885POLB 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.